Maraviroc, a CCR5 blocker approved by the United States Food and Drug Administration (FDA) for the treatment of HIV infection, can attenuate glioma-induced microglial migration and reverse M2 polarisation [92]. The gene discussed is CCR5; the disease is glioma.